Blog
About

48
views
0
recommends
+1 Recommend
1 collections
    2
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Quantification of Panax notoginseng saponins metabolites in rat plasma with in vivo gut microbiota-mediated biotransformation by HPLC-MS/MS

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Panax notoginseng saponins (PNS) are the major components of Panax notoginseng, with multiple pharmacological activities but poor oral bioavailability. PNS could be metabolized by gut microbiota in vitro, while the exact role of gut microbiota of PNS metabolism in vivo remains poorly understood. In this study, pseudo germ-free rat models were constructed by using broad-spectrum antibiotics to validate the gut microbiota-mediated transformation of PNS in vivo. Moreover, a high performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) was developed for quantitative analysis of four metabolites of PNS, including ginsenoside F1 (GF1), ginsenoside Rh2 (GRh2), ginsenoside compound K (GCK) and proto-panaxatriol (PPT). The results showed that the four metabolites could be detected in the control rat plasma, while they could not be determined in pseudo germ-free rat plasma. The results implied that PNS could not be biotransformed effectively when gut microbiota was disrupted. In conclusion, gut microbiota plays an important role in biotransformation of PNS into metabolites in vivo.

          Related collections

          Author and article information

          Journal
          CJNM
          Chinese Journal of Natural Medicines
          Elsevier
          1875-5364
          20 March 2019
          : 17
          : 3
          : 231-240
          Affiliations
          1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
          2 Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
          3 Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410128, China
          Author notes
          *Corresponding author: HUANG Wei-Hua, Tel: 86-731-84805380, Fax: 86-731-82354476; E-mail: endeavor34852@ 123456aliyun.com

          ΔThese authors contributed to the work equally.

          These authors have no conflict of interest to declare.

          Article
          S1875-5364(19)30026-3
          10.1016/S1875-5364(19)30026-3
          Copyright © 2019 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funding
          Funded by: National Natural Science Foundation of China
          Award ID: 31400306
          Funded by: Hunan Provincial Natural Science Foundation of China
          Award ID: 2015JJ3156
          Funded by: China Postdoctoral Science Foundation
          Award ID: 2015M 570692
          This work was supported by the National Natural Science Foundation of China (No. 31400306), Hunan Provincial Natural Science Foundation of China (2015JJ3156), and China Postdoctoral Science Foundation (2015M 570692).

          Comments

          Comment on this article